Trials / Completed
CompletedNCT06892119
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Dose-reduced Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma and Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Generic plerixafor use at reduced-dose for mobilization on HSCT transplant
Detailed description
The objective of this study is to demonstrate that the use of a low dose of the generic form of a drug called plerixafor is effective in increasing the amount of hematopoietic cells (stem cells) in your blood, which will then be collected for your transplant. Plerixafor is a very effective medicine that is already used for this purpose, however its high cost limits its use in all patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celrixafor | Use a reduced-dose of generic plerixafor |
Timeline
- Start date
- 2019-12-09
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2025-03-24
- Last updated
- 2025-03-27
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT06892119. Inclusion in this directory is not an endorsement.